WO2010038155A3 - Anticorps contre il-25 - Google Patents

Anticorps contre il-25 Download PDF

Info

Publication number
WO2010038155A3
WO2010038155A3 PCT/IB2009/007302 IB2009007302W WO2010038155A3 WO 2010038155 A3 WO2010038155 A3 WO 2010038155A3 IB 2009007302 W IB2009007302 W IB 2009007302W WO 2010038155 A3 WO2010038155 A3 WO 2010038155A3
Authority
WO
WIPO (PCT)
Prior art keywords
target binding
binding members
antibodies
antibodies against
domains
Prior art date
Application number
PCT/IB2009/007302
Other languages
English (en)
Other versions
WO2010038155A2 (fr
Inventor
David John Matthews
Jillian Barlow
Andrew Neil James Mckenzie
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES09795802.9T priority Critical patent/ES2537226T3/es
Priority to CN200980147932.6A priority patent/CN102245638B/zh
Priority to CA2739050A priority patent/CA2739050C/fr
Priority to BRPI0919062A priority patent/BRPI0919062A2/pt
Priority to AU2009299465A priority patent/AU2009299465B2/en
Priority to US13/121,898 priority patent/US8658169B2/en
Priority to EP09795802.9A priority patent/EP2344538B1/fr
Priority to KR1020117009937A priority patent/KR101659452B1/ko
Priority to MX2011003351A priority patent/MX2011003351A/es
Priority to RS20150341A priority patent/RS54028B1/en
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to MEP-2015-78A priority patent/ME02219B/me
Priority to PL09795802T priority patent/PL2344538T3/pl
Priority to JP2011528454A priority patent/JP5719771B2/ja
Priority to DK09795802.9T priority patent/DK2344538T3/en
Priority to NZ592274A priority patent/NZ592274A/xx
Priority to SI200931196T priority patent/SI2344538T1/sl
Publication of WO2010038155A2 publication Critical patent/WO2010038155A2/fr
Publication of WO2010038155A3 publication Critical patent/WO2010038155A3/fr
Priority to HK11108260.3A priority patent/HK1154022A1/xx
Priority to HRP20150524TT priority patent/HRP20150524T1/hr
Priority to SM201500144T priority patent/SMT201500144B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La présente invention concerne des domaines VH d’anticorps anti-IL-25 et des éléments de liaison de cible (par exemple, des anticorps) qui comprennent de tels domaines VH d’anticorps et se lient à IL-25. L’invention concerne en outre des compositions comprenant des éléments de liaison de cible (par exemple, des anticorps) qui se lient à IL-25, des procédés de production de tels éléments de liaison de cible, et des utilisations de tels éléments de liaison de cible pour le traitement ou la prévention de maladies et d’affections (par exemple, l’asthme, l’affection abdominale inflammatoire).
PCT/IB2009/007302 2008-09-30 2009-09-30 Anticorps contre il-25 WO2010038155A2 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
MEP-2015-78A ME02219B (me) 2008-09-30 2009-09-30 Antitela protiv il-25
CN200980147932.6A CN102245638B (zh) 2008-09-30 2009-09-30 针对il-25的抗体
BRPI0919062A BRPI0919062A2 (pt) 2008-09-30 2009-09-30 anticorpos contra il-25
AU2009299465A AU2009299465B2 (en) 2008-09-30 2009-09-30 Antibodies against IL-25
US13/121,898 US8658169B2 (en) 2008-09-30 2009-09-30 Antibodies against IL-25
EP09795802.9A EP2344538B1 (fr) 2008-09-30 2009-09-30 Anticorps contre il-25
KR1020117009937A KR101659452B1 (ko) 2008-09-30 2009-09-30 Ｉｌ－２５에 대한 항체
PL09795802T PL2344538T3 (pl) 2008-09-30 2009-09-30 Przeciwciała przeciwko IL-25
RS20150341A RS54028B1 (en) 2008-09-30 2009-09-30 ANTIBODIES AGAINST IL-25
ES09795802.9T ES2537226T3 (es) 2008-09-30 2009-09-30 Anticuerpos contra IL-25
CA2739050A CA2739050C (fr) 2008-09-30 2009-09-30 Anticorps contre il-25
MX2011003351A MX2011003351A (es) 2008-09-30 2009-09-30 Anticuerpos contra il-25.
JP2011528454A JP5719771B2 (ja) 2008-09-30 2009-09-30 Ｉｌ−２５に対する抗体
DK09795802.9T DK2344538T3 (en) 2008-09-30 2009-09-30 ANTIBODIES AGAINST IL-25
NZ592274A NZ592274A (en) 2008-09-30 2009-09-30 Antibodies against interleukin-25
SI200931196T SI2344538T1 (sl) 2008-09-30 2009-09-30 Protitelesa proti IL-25
HK11108260.3A HK1154022A1 (en) 2008-09-30 2011-08-08 Antibodies against il-25 il-25
HRP20150524TT HRP20150524T1 (hr) 2008-09-30 2015-05-15 Protutijela za il-25
SM201500144T SMT201500144B (it) 2008-09-30 2015-06-18 Anticorpi contro IL-25

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10129308P 2008-09-30 2008-09-30
GB0817891.5 2008-09-30
GBGB0817891.5A GB0817891D0 (en) 2008-09-30 2008-09-30 Antibodies against il-25
US61/101,293 2008-09-30

Publications (2)

Publication Number Publication Date
WO2010038155A2 WO2010038155A2 (fr) 2010-04-08
WO2010038155A3 true WO2010038155A3 (fr) 2010-05-27

Family

ID=40019808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/007302 WO2010038155A2 (fr) 2008-09-30 2009-09-30 Anticorps contre il-25

Country Status (23)

Country Link
US (1) US8658169B2 (fr)
EP (1) EP2344538B1 (fr)
JP (1) JP5719771B2 (fr)
KR (1) KR101659452B1 (fr)
CN (1) CN102245638B (fr)
AU (1) AU2009299465B2 (fr)
BR (1) BRPI0919062A2 (fr)
CA (1) CA2739050C (fr)
CY (1) CY1116313T1 (fr)
DK (1) DK2344538T3 (fr)
ES (1) ES2537226T3 (fr)
GB (1) GB0817891D0 (fr)
HK (1) HK1154022A1 (fr)
HR (1) HRP20150524T1 (fr)
ME (1) ME02219B (fr)
MX (1) MX2011003351A (fr)
NZ (1) NZ592274A (fr)
PL (1) PL2344538T3 (fr)
PT (1) PT2344538E (fr)
RS (1) RS54028B1 (fr)
SI (1) SI2344538T1 (fr)
SM (1) SMT201500144B (fr)
WO (1) WO2010038155A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
SI2552961T1 (en) * 2010-03-30 2018-02-28 Janssen Biotech, Inc. Humanized antibodies against IL-25
JP6284181B2 (ja) * 2012-02-09 2018-02-28 国立研究開発法人理化学研究所 環状ｒｎａ及びタンパク質の製造方法
CN103792375B (zh) * 2014-01-29 2017-07-07 华中科技大学同济医学院附属同济医院 外周血白细胞介素25水平在哮喘分型中的应用及分型方法
JP6694877B2 (ja) 2014-09-23 2020-05-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｉｌ−２５抗体およびその使用
EP3430046A4 (fr) * 2016-03-16 2019-10-23 Abeome Corporation Anticorps monoclonaux neutralisants dirigés contre l'il-25 et leurs utilisations
WO2018017864A2 (fr) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Agents de liaison à pvrig et leurs utilisations
WO2018018082A1 (fr) 2016-07-26 2018-02-01 The Australian National University Compositions immunostimulantes et utilisations de celles-ci
AU2018450414A1 (en) * 2018-11-19 2021-05-20 Beijing Kanova Biopharmaceutical Co., Ltd. Anti-IL-25 antibodies and use thereof
GB202018015D0 (en) 2020-11-16 2020-12-30 Res & Innovation Uk Composition and methods for the treatment of intestinal cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044450A2 (fr) * 2005-10-06 2007-04-19 Baylor Research Institute Compositions et methodes pour le traitement du cancer
WO2008129263A1 (fr) * 2007-04-18 2008-10-30 Medical Research Council Anticorps dirigés contre il-25

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0276846A3 (fr) 1987-01-29 1989-07-26 Zymogenetics, Inc. Dérivés du facteur stimulant des colonies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
NZ542988A (en) 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
CA2599754C (fr) 2005-03-08 2012-06-19 Genesense Technologies Inc. Utilisation de l'interleukine 17e pour le traitement du cancer
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
SI2552961T1 (en) * 2010-03-30 2018-02-28 Janssen Biotech, Inc. Humanized antibodies against IL-25
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044450A2 (fr) * 2005-10-06 2007-04-19 Baylor Research Institute Compositions et methodes pour le traitement du cancer
WO2008129263A1 (fr) * 2007-04-18 2008-10-30 Medical Research Council Anticorps dirigés contre il-25

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALMAGRO JUAN C ET AL: "Humanization of antibodies", FRONTIERS IN BIOSCIENCE, FRONTIERS IN BIOSCIENCE, ALBERTSON, NY, US, vol. 13, 1 January 2008 (2008-01-01), pages 1619 - 1633, XP009126790, ISSN: 1093-9946 *
BALLANTYNE ET AL: "Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US, vol. 120, no. 6, 1 December 2007 (2007-12-01), pages 1324 - 1331, XP022383425, ISSN: 0091-6749 *
DALL'ACQUA W F ET AL: "Antibody humanization by framework shuffling", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 36, no. 1, 1 May 2005 (2005-05-01), pages 43 - 60, XP004852552, ISSN: 1046-2023 *
DAVIES J ET AL: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, 1 September 1996 (1996-09-01), pages 169 - 179, XP004070292, ISSN: 1380-2933 *
HOLT L J ET AL: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484 - 490, XP004467495, ISSN: 0167-7799 *
LAZAR G A ET AL: "A molecular immunology approach to antibody humanization and functional optimization", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 8, 1 March 2007 (2007-03-01), pages 1986 - 1998, XP002540093, ISSN: 0161-5890, [retrieved on 20061031] *

Also Published As

Publication number Publication date
CA2739050C (fr) 2018-05-29
MX2011003351A (es) 2011-05-25
NZ592274A (en) 2012-08-31
JP2012503979A (ja) 2012-02-16
BRPI0919062A2 (pt) 2015-12-15
WO2010038155A2 (fr) 2010-04-08
PL2344538T3 (pl) 2015-10-30
ME02219B (me) 2016-02-20
SI2344538T1 (sl) 2015-07-31
PT2344538E (pt) 2015-06-19
US20110250195A1 (en) 2011-10-13
JP5719771B2 (ja) 2015-05-20
ES2537226T3 (es) 2015-06-03
HRP20150524T1 (hr) 2015-08-14
KR101659452B1 (ko) 2016-09-23
CA2739050A1 (fr) 2010-04-08
DK2344538T3 (en) 2015-06-01
RS54028B1 (en) 2015-10-30
AU2009299465B2 (en) 2012-07-26
AU2009299465A1 (en) 2010-04-08
EP2344538B1 (fr) 2015-02-25
GB0817891D0 (en) 2008-11-05
SMT201500144B (it) 2015-09-07
CY1116313T1 (el) 2017-02-08
US8658169B2 (en) 2014-02-25
CN102245638B (zh) 2014-10-22
EP2344538A2 (fr) 2011-07-20
HK1154022A1 (en) 2012-04-13
CN102245638A (zh) 2011-11-16
KR20110086013A (ko) 2011-07-27

Similar Documents

Publication Publication Date Title
WO2010038155A3 (fr) Anticorps contre il-25
WO2008070344A3 (fr) Compositions et procédés permettant une liaison sphingosine-1-phosphate
WO2011004028A3 (fr) Agents de liaison à tlr3
WO2010006060A3 (fr) Immunoglobulines à double domaine variable de prostaglandine e2 et leurs utilisations
WO2009155180A8 (fr) Anticorps anti-il-6 et leurs utilisations
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
WO2009151717A3 (fr) Anticorps spécifiques du complexe bcr et procédés pour les utiliser
WO2008079246A3 (fr) Anticorps anti-cd44
WO2009149189A3 (fr) Immunoglobulines à deux domaines variables et leurs utilisations
WO2009134776A3 (fr) Immunoglobulines à double domaine variable et utilisations
WO2009149185A3 (fr) Immunoglobulines à double domaine variable et leurs utilisations
WO2010136311A3 (fr) Compositions et procédés de ciblage de la protéine c3b de complément par des anticorps
WO2011059755A3 (fr) Immunoglobulines doubles de domaine variable et utilisations de celles-ci
WO2011050262A3 (fr) Immunoglobulines à domaine variable double et utilisations de celles-ci
WO2011047262A3 (fr) Immunoglobulines à deux domaines variables et utilisations afférentes
WO2011014659A3 (fr) Immunoglobulines à double domaine variable et utilisations de celles-ci
WO2010127284A3 (fr) Immunoglobulines à deux domaines variables et ses utilisations
WO2013011076A3 (fr) Protéines de liaison à un antigène ayant une liaison accrue à fcrn
WO2010066803A3 (fr) Anticorps humains du facteur tissulaire
WO2011028811A3 (fr) Immunoglobulines à double domaine variable et leurs utilisations
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
WO2006096489A3 (fr) Compositions d'anticorps anti-m-csf a niveaux d'endotoxine reduits
WO2011163478A3 (fr) Immunoglobulines à double domaine variable et utilisations associées
WO2008025020A3 (fr) agents de liaison de CD30 et leurs usages
WO2010021697A3 (fr) Anticorps anti-ccr2

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980147932.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2011528454

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/003351

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2739050

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009299465

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2671/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 592274

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2009795802

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117009937

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009299465

Country of ref document: AU

Date of ref document: 20090930

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13121898

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P-2015/0341

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0919062

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110325